Published August 2011 | Version v1
Journal article

Evaluation of implanted gold seeds for breast radiotherapy planning and on treatment verification: A feasibility study on behalf of the IMPORT trialists

  • 1. Cambridge University Hospitals NHS Foundation Trust, Cambridge (United Kingdom)
  • 2. Royal Marsden NHS Trust and Institute of Cancer Research, Cambridge (United Kingdom)
  • 3. Torbay Hospital, Cambridge (United Kingdom)
  • 4. Ipswich Hospital NHS Trust, Cambridge (United Kingdom)
  • 5. Clatterbridge Centre for Oncology, Cambridge (United Kingdom)
  • 6. Centre for Applied Medical Statistics, Cambridge (United Kingdom)

Description

Background and purpose: We describe a feasibility study testing the use of gold seeds for the identification of post-operative tumour bed after breast conservation surgery (BCS). Materials and Methods: Fifty-three patients undergoing BCS for invasive cancer were recruited. Successful use was defined as all six seeds correctly positioned around the tumour bed during BCS, unique identification of all implanted seeds on CT planning scan and ≥3 seeds uniquely identified at verification to give couch displacement co-ordinates in 10/15 fractions. Planning target volume (PTV) margin size for four correction strategies were calculated from these data. Variability in tumour bed contouring was investigated with five radiation oncologists outlining five CT datasets. Results: Success in inserting gold seeds, identifying them at CT planning and using them for on-treatment verification was recorded in 45/51 (88%), 37/38 (97%) and 42/43 (98%) of patients, respectively. The clinicians unfamiliar with CT breast planning consistently contoured larger volumes than those already trained. Margin size ranged from 10.1 to 1.4 mm depending on correction strategy. Conclusion: It is feasible to implant tumour bed gold seeds during BCS. Whilst taking longer to insert than surgical clips, they have the advantage of visibility for outlining and verification regardless of the ionising radiation beam quality. Appropriate correction strategies enable margins of the order of 5 mm as required by the IMPORT trials however, tackling clinician variability in contouring is important.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.radonc.2011.03.007

Additional details

Identifiers

DOI
10.1016/j.radonc.2011.03.007;
PII
S0167-8140(11)00128-9;

Publishing Information

Journal Title
Radiotherapy and Oncology
Journal Volume
100
Journal Issue
2
Journal Page Range
p. 276-281
ISSN
0167-8140
CODEN
RAONDT

INIS

Country of Publication
Ireland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
43064786
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
EVALUATION; FEASIBILITY STUDIES; GOLD; IMAGES; IMPLANTS; IONIZING RADIATIONS; MAMMARY GLANDS; MEDICAL PERSONNEL; NEOPLASMS; PATIENTS; RADIOTHERAPY; SURGERY
Descriptors DEC
BODY; DISEASES; ELEMENTS; GLANDS; MEDICINE; METALS; NUCLEAR MEDICINE; ORGANS; PERSONNEL; RADIATIONS; RADIOLOGY; THERAPY; TRANSITION ELEMENTS

Optional Information

Copyright
Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.